PMI appoints Matthew Holman as Vice President of Regulatory Strategy

Sep.20.2022
PMI appoints Matthew Holman as Vice President of Regulatory Strategy
Matthew Holman leaves FDA role to become PMI's US Science Engagement and Regulatory Strategy VP as the company seeks to promote safer nicotine alternatives.

Matthew Holman has left his position at the FDA to become the Vice President of Scientific Engagement and Regulatory Strategy for PMI in the United States.


Of course, considering the tobacco companies are currently facing strict regulations and public scrutiny, these appointments are crucial. Badrul Chowdhury, who has worked at the FDA for over 20 years, has accepted the position of Chief Life Sciences Officer, while Matthew Holman has been appointed as Vice President of Science Engagement and Regulatory Strategy for the tobacco company in the United States.


In recent years, Philip Morris International (PMI) has been making efforts to improve its image and reputation by turning towards the sale of safer nicotine alternatives. Former CEO Andre Catantzopoulos believed that a smokeless future is possible and that achieving a consensus with the government and society is necessary through proper supervision and regulation. He stated that alternative nicotine products can be a part of effective tobacco policy. "Thanks to rapid progress in science and technology, and PMI's firm commitment, these products have now become a reality," he said.


Although current CEO of PMI, Jacek Olczak, has stated that the tobacco company intends to achieve its goal of 50% smoke-free product sales by 2025, he also claims the company is fully capable of replacing cigarettes with safer alternatives. "We have a leading portfolio of traditional and smoke-free tobacco products, an excellent management team, and an agile, efficient, and quick-learning organization. We are fully capable of continuing to succeed in our vision of replacing cigarettes with better alternatives for the benefit of consumers, shareholders, and society," he stated earlier this year, quoted by The Edge.


PMI is working hard to change its image.


Last year, PMI received criticism from the British Asthma Association and British Lung Foundation for their collaboration with asthma inhaler manufacturer Vectura. This move appeared hypocritical, as the investment was in a product that could help treat tobacco-related diseases.


Meanwhile, Altria has recently reiterated its plan to enter the healthcare field, stating that this is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a more holistic lifestyle, consumer health, and healthcare company in the future. This evolution is not only fulfilling our continued commitment to a smoke-free future but also fulfilling the development and commercialization of scientifically validated products and solutions to meet unmet consumer and patient needs.


The market for health and wellness products is vast and constantly expanding. We have several key areas of focus in our pipeline. For consumers and over-the-counter healthcare products, we have several initiatives focused on concentration, sleep, energy, pain relief, and calmness. In the healthcare field, we believe that patients' demand for fast and effective treatments for cardiovascular diseases such as myocardial infarction and neurological conditions such as migraines has yet to be met, and innovative solutions can meet these needs. We recently accelerated this part of our strategy through the acquisition of Vectura, an innovative inhalation delivery solution provider, and Fertin, a leading developer and manufacturer of innovative drugs and healthcare products based on oral and intraoral delivery systems," said Alzack.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for communication and research within the industry.


Due to limitations in translation abilities, the translated article may not fully express the original text, so please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions relating to domestic issues, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.
Apr.23 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
Australia Quantifies Black Market for First Time, Illicit Nicotine Products Account for About 80% of Consumption
Australia Quantifies Black Market for First Time, Illicit Nicotine Products Account for About 80% of Consumption
The Australian Bureau of Statistics (ABS) has released its first estimate of the illicit nicotine market, finding that about 80% of cigarettes, vapes and other nicotine products consumed in 2025 came from illegal sources, reigniting debate over tobacco taxation and enforcement policies.
Jun.03
Exhibition Insights | Geek Bar Booth Shows Two Fasoul Heat-Not-Burn Devices in Prague
Exhibition Insights | Geek Bar Booth Shows Two Fasoul Heat-Not-Burn Devices in Prague
At EVO NXT 2026 in Prague, the Geek Bar booth displayed two Fasoul heat-not-burn devices, Q1 Pro and C2. One stressed compact size, screen-led control and dual modes, while the other highlighted faster heating, a larger battery and added functions. Both were presented as compatible with IQOS TEREA and SENTIA sticks. Materials on a website displaying Fasoul-related information also show recent market activity in Japan and Italy.
Apr.20 by 2FIRSTS.ai
FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
The U.S. Food and Drug Administration released a programmatic environmental assessment covering nicotine pouches and other oral nicotine products, concluding that their overall environmental impact is generally minimal.
Regulations
May.22